Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Swedish Orphan Biovitrum publ AB's Kiobrina pivotal phase three study did not meet primary endpoint


Wednesday, 26 Mar 2014 08:08am EDT 

Swedish Orphan Biovitrum publ AB:Announces topline data from its pivotal phase three study of its enzyme therapy Kiobrina (rhBSSL - recombinant human Bile Salt Stimulated Lipase).Primary endpoint of the study - growth velocity measured after four weeks of treatment with rhBSSL - was not met.No statistically significant improvement in growth velocity was demonstratedin preterm infants treated with rhBSSL compared to placebo. 

Company Quote

75.35
-0.95 -1.25%
24 Oct 2014